

Ya-Chun Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6303058/publications.pdf>

Version: 2024-02-01

32
papers

1,285
citations

430874

18
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

1348
citing authors

#	ARTICLE	IF	CITATIONS
1	PACS-2 Ameliorates Tubular Injury by Facilitating Endoplasmic Reticulum-Mitochondria Contact and Mitophagy in Diabetic Nephropathy. <i>Diabetes</i> , 2022, 71, 1034-1050.	0.6	29
2	PRDM16 Regulating Adipocyte Transformation and Thermogenesis: A Promising Therapeutic Target for Obesity and Diabetes. <i>Frontiers in Pharmacology</i> , 2022, 13, 870250.	3.5	9
3	Mitochondrial DNA-dependent inflammation in kidney diseases. <i>International Immunopharmacology</i> , 2022, 107, 108637.	3.8	2
4	Effects of family history of diabetes on pancreatic β -cell function and diabetic ketoacidosis in newly diagnosed patients with type 2 diabetes: a cross-sectional study in China. <i>BMJ Open</i> , 2021, 11, e041072.	1.9	4
5	MAMs Protect Against Ectopic Fat Deposition and Lipid-Related Kidney Damage in DN Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 609580.	3.5	14
6	DsbA-L Ameliorates Renal Injury Through the AMPK/NLRP3 Inflammasome Signaling Pathway in Diabetic Nephropathy. <i>Frontiers in Physiology</i> , 2021, 12, 659751.	2.8	15
7	Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy. <i>Current Medicinal Chemistry</i> , 2021, 28, 1003-1024.	2.4	4
8	Effects of HIF-1 α on renal fibrosis in cisplatin-induced chronic kidney disease. <i>Clinical Science</i> , 2021, 135, 1273-1288.	4.3	19
9	Targeting the NLRP3 Inflammasome in Diabetic Nephropathy. <i>Current Medicinal Chemistry</i> , 2021, 28, 8810-8824.	2.4	14
10	AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. <i>Cell Death and Disease</i> , 2021, 12, 925.	6.3	77
11	Lipophagy deficiency exacerbates ectopic lipid accumulation and tubular cells injury in diabetic nephropathy. <i>Cell Death and Disease</i> , 2021, 12, 1031.	6.3	37
12	Caveolin-1 Regulates Cellular Metabolism: A Potential Therapeutic Target in Kidney Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 768100.	3.5	16
13	Family history of diabetes is associated with diabetic foot complications in type 2 diabetes. <i>Scientific Reports</i> , 2020, 10, 17056.	3.3	11
14	Mitochondria-Associated ER Membranes - The Origin Site of Autophagy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 595.	3.7	75
15	Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury via regulating mitochondrial ROS-NLRP3 pathway. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110521.	5.6	54
16	Aristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF-1 α . <i>FASEB Journal</i> , 2020, 34, 12599-12614.	0.5	19
17	HIF-1 α ameliorates tubular injury in diabetic nephropathy via HO-1-mediated control of mitochondrial dynamics. <i>Cell Proliferation</i> , 2020, 53, e12909.	5.3	74
18	AdipoRon Protects against Tubular Injury in Diabetic Nephropathy by Inhibiting Endoplasmic Reticulum Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-15.	4.0	6

#	ARTICLE	IF	CITATIONS
19	The Relationship Between Simple Renal Cysts and Renal Function in Patients With Type 2 Diabetes. <i>Frontiers in Physiology</i> , 2020, 11, 616167.	2.8	6
20	Mitochondria-Targeted Peptide SS31 Attenuates Renal Tubulointerstitial Injury via Inhibiting Mitochondrial Fission in Diabetic Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-13.	4.0	33
21	Association of Vitamin D Receptor Gene Polymorphism With the Risk of Nephrolithiasis. <i>Therapeutic Apheresis and Dialysis</i> , 2019, 23, 425-436.	0.9	4
22	DsbA-L ameliorates high glucose induced tubular damage through maintaining MAM integrity. <i>EBioMedicine</i> , 2019, 43, 607-619.	6.1	53
23	Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy. <i>Kidney International</i> , 2019, 95, 880-895.	5.2	54
24	Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis. <i>Redox Biology</i> , 2018, 16, 32-46.	9.0	269
25	Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue. <i>Therapeutic Apheresis and Dialysis</i> , 2018, 22, 124-132.	0.9	19
26	The Susceptibility Genes in Diabetic Nephropathy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2018, 4, 226-237.	2.5	51
27	Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases. <i>Current Medicinal Chemistry</i> , 2018, 25, 3256-3271.	2.4	64
28	Normoalbuminuric diabetic kidney disease. <i>Frontiers of Medicine</i> , 2017, 11, 310-318.	3.4	85
29	Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc. <i>Redox Biology</i> , 2017, 13, 482-497.	9.0	43
30	Red cell distribution width as a significant indicator of medication and prognosis in type 2 diabetic patients. <i>Scientific Reports</i> , 2017, 7, 2709.	3.3	21
31	Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy. <i>Current Medicinal Chemistry</i> , 2017, 24, 3185-3202.	2.4	58
32	p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy. <i>Scientific Reports</i> , 2016, 6, 29302.	3.3	36